74 results about "Cachexia" patented technology

The invention relates to an application of an amide substituted 2-oxopyridine compound. Specifically, a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, an optically pure isomer, a stereoisomer or a mixture thereof, is used for preparing a medicine or a preparation, and the medicine or the preparation is used for one or more of the following applications: (a) a medicine for treating and / or preventing cachexia-related diseases, (b) a medicine for treating and / or preventing cachexia-related diseases, (c) a medicine for treating and / or preventing cachexia-related diseases, and (c) a medicine for treating and / or preventing cachexia-related diseases; (b) inhibiting the browning of fat cells; and / or (c) promoting the degradation of the PRDM16 protein; wherein the compound shown in the formula (I) has a structure shown in the specification,

The present invention relates to novel use of a cathepsin L inhibitor Z-Phe-Tyr-CHO (C26H26N2O5), wherein the cathepsin L inhibitor Z-Phe-Tyr-CHO inhibits cancer progression and cachexia and muscle damage that are caused by cancer, and thus can be effectively used for preventing, ameliorating or treating cachexia and muscle loss, while having anticancer activity.

The invention discloses a marker for combined diagnosis of pancreatic cancer cachexia. The research finds that the serum pancreatic cancer exosome miR-203a-3p can be used for diagnosing pancreatic cancer cachexia or early stage of pancreatic cancer cachexia independently or in combination with nutrition inflammation indexes, and has relatively high diagnosis efficiency, and the diagnosis efficiency is greatly improved after the miR-203a-3p is combined with other indexes; a new direction is provided for effective diagnosis and treatment of pancreatic cancer cachexia or precachexia of pancreatic cancer, and the application prospect is wide.

The present application relates to a kind of water gel based on crude polysaccharide of Radix Trichosanthis and its preparation method and application.The water gel based on crude polysaccharide of Radix Trichosanthis is prepared by the following method:1) preparing crude polysaccharide of Radix Trichosanthis;2) making aldehyde group of crude polysaccharide of Radix Trichosanthis to obtain aldehyde group of crude polysaccharide of Radix Trichosanthis;And 3) aldehyde group of crude polysaccharide of Radix Trichosanthis and carboxymethyl cellulose are covalently combined to form the water gel by Schiff base reaction.The multifunctional water gel of the present application is expected to become the candidate dressing of clinical protection and treatment of cachexia wound and other immunosuppressive chronic wound.

Nucleotide sequences including a micro-dystrophin gene are provided. The micro-dystrophin genes may be operatively linked to a regulatory cassette. Methods of treating a subject having, or at risk of developing, muscular dystrophy, sarcopenia, heart disease, or cachexia are also provided. The methods may include administering a pharmaceutical composition including the micro-dystrophin gene and a delivery vehicle to a subject. Further, the methods may include administering the pharmaceutical composition a subject having Duchenne muscular dystrophy or Becker muscular dystrophy.

To provide Akt3 modulators and compounds and pharmaceutical compositions for treating diseases by modulation of Akt3 signaling.SOLUTION: A compound of Formula Ib or Ic, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound for treating a disease in a subject in need thereof, A pharmaceutical composition wherein the treatment comprises administering to a subject an effective amount of the compound; optionally wherein the disease is selected from the group consisting of neurodegenerative diseases, cachexia, eating disorders, obesity, complications of obesity, inflammatory diseases, virally-induced inflammatory reactions, Gulf War Syndrome, tuberous sclerosis, retinitis pigmentosa, graft rejection, cancer, autoimmune diseases, ischemic tissue injury, traumatic tissue injury and combinations thereof.SELECTED DRAWING: Figure 6

The application provides application of ABT199 in preparation of a drug for treating muscle atrophy. Compared with the prior art, the application provides a new use of ABT199 in treating muscle atrophy. Experimental research proves that ABT199 administration can significantly restore the exercise capacity of a cachexia-induced muscle atrophy mouse, improve the muscle cross-sectional area of the mouse, restore the reduced glutathione content of the mouse, and improve the superoxide dismutase activity, so as to improve the muscle atrophy phenotype of the mouse and muscle atrophy-related biochemical indexes. ABT199 can significantly restore cell muscle atrophy-related gene and protein expression, and improve the cachexia-induced muscle atrophy phenotype by reducing related inflammatory mediators; ABT199 can significantly improve the mitochondrial membrane potential, increase the expression of mitochondrial neogenesis-related genes, and reduce the production of active oxygen.

To provide a new compound useful for treating cachexia or wasting syndrome which is a severe complication of chronic diseases such as neurodegenerative diseases and cancer.SOLUTION: Compounds of formula Ib or Ic are described. The compounds can modify the Akt3 or effects of nature in vitro or in vivo, and can also be used, alone or in combination with other agents, in the prevention or treatment of various conditions.SELECTED DRAWING: Figure 1

The invention relates to the technical field of medical health, in particular to an intelligent evaluation and intervention system for muscle quality of a patient with advanced solid tumors. The multi-dimensional dynamic evaluation unit is used for forming the extracted somatic cell mass, the score of the anorexia-cachexia syndrome, the standardized skeletal muscle index and the average muscle radiation attenuation value into multi-dimensional feature data, and the multi-dimensional dynamic evaluation unit is used for evaluating the quality of the somatic cells on the basis of the multi-dimensional feature data and fusing tumor treatment scheme data. Generating a multi-dimensional muscle health index and a malignant fluid risk probability through a decision tree model, and dividing patients into different risk levels; and the intervention strategy generation unit is used for outputting a comprehensive intervention scheme based on the multi-dimensional muscle health index and the malignant fluid risk probability in combination with the real-time tolerance data and the risk level of the patient. According to the system, the L3 level skeletal muscle index and the muscle radiation attenuation value can be extracted more accurately and stably, manual annotation and manual variation are reduced, and the reliability of image quantification is improved.

Described herein are treatment regimens, therapies, pharmaceutical formulations and methods of using quercetin to prevent, treat, and / or protect from muscle wasting including 1) sarcopenia associated with aging; and 2) cachexia associated with chronic diseases and their treatments including but not limited to cancer, cardiovascular disease, chronic obstructive pulmonary disease (COPD), HIV, and kidney disease.

The present invention relates to a pharmaceutically acceptable acid addition salt comprising: (i) S-indolylcarbamate; and (ii) an organic acid, wherein the organic acid has: a pKa1 greater than or equal to 2.5; and a chemical formula of CxHy(CO2H)z, wherein x is 1 to 10, y is 2 to 20, and z is 1 or 2. The pharmaceutically acceptable acid addition salt is used to treat conditions such as cachexia, sarcopenia, neuromuscular disorders, and muscle weakness.

The application provides a kinase inhibitor leading compound, a virtual screening method thereof and application of the kinase inhibitor leading compound in preparation of branched-chain alpha-keto acid dehydrogenase kinase inhibitors and / or drugs for treating diseases mediated by branched-chain alpha-keto acid dehydrogenase kinase. The virtual screening method provided by the application combines various virtual screening platforms to screen a large-scale compound library, improves the true positive rate of screening results, reduces the number of compounds needing experimental screening, and saves screening time and cost. In addition, the compounds I-III screened out with good binding affinity to BCKDK can be used in researches on targeting BCKDK to treat major diseases such as obesity, insulin resistance, maple syrup urine disease, neurological dysfunction, liver cancer, colorectal cancer and tumor cachexia.

The invention provides application and an application method of nucleic acid in preparation of a medicine for preventing and treating malignant fluid. According to the nucleic acid disclosed by the invention, in-vivo malignant fluid related factors are regulated through oligonucleotides contained or generated by the nucleic acid, an autologous reprogramming state is started, and by regulating activity / silence of key nucleic acid factors, a non-coding RNA regulation and control signal programming network is realized, and the purpose of regulating and controlling a plurality of signal channels by a single non-coding RNA is realized; and thus, a new steady state of the maladjustment physiological state is reconstructed. Compared with other nucleic acid drugs, the drug taking the nucleic acid as the active component has the advantages that the dosage is extremely small in the prevention and treatment process, the drug safety is ensured on the basis of achieving the drug effect, and the current situation of traditional plasmid / nucleic acid drug administration is subverted. In addition, the nucleic acid provided by the invention has no specific reaction, and has relatively high in-vivo safety.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for replenishing qi, enriching blood, tonifying spleen and nourishing kidney as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 2 to 12 parts of radix angelicae sinensis, 5 to 20 parts of radix codonopsis, 5 to 20 parts of radix astragali seu hedysari, 2 to 12 parts of rhizoma atractylodis macrocephalae, 2 to 15 parts of poria cocos, 3 to 13 parts of colla corii asini, 3 to 13 parts of tortoise-shell glue, 2 to 12 parts of herba cistanche, 5 to 15 parts of radix rehmanniae praeparata, 3 to 15 parts of rhizoma polygonati, 3 to 13 parts of herba epimedii, 2 to 12 parts of fructus crataegi, 5 to 15 parts of arillus longan, 2 to 12 parts of fructus ligustri lucidi, 2 to 6 parts of fructus schisandrae chinensis and 1 to 5 parts of cortex cinnamomi. The traditional Chinese medicine composition has the main effects of replenishing qi, enriching blood, tonifying spleen and nourishing kidney, is used for rehabilitation after cancer surgery or chemotherapy and used for resisting cancer relapse, is particularly used for patients with spleen and kidney deficiency type cachexia after cancer surgery or chemotherapy, and improves the problems of emaciation, insomnia, inappetence, mental fatigue and tiredness and the like of the patients with the patients with the spleen and kidney deficiency type cachexia after cancer surgery or chemotherapy.

The present invention provides a GDF15-binding nanoantibody, and a use thereof in preparation of a drug for treating tumor cachexia and in detection of GDF15. The nanoantibody provided in the present invention exhibits high affinity for GDF-15 and is capable of blocking the binding of GDF-15 to GFRAL.

The invention relates to an iodinated CT contrast agent for non-invasive diagnosis of cachexia. This is possible by superior resolution of CT combined with CT contrast agent specific for the brown and / or beige adipose tissue (BAT).

The present invention discloses a traditional Chinese medicine, Moutanpi (Moutan radicis cort), which has potential use in preventing or treating cachexia and muscle loss in cancer patients. The composition is a novel treatment for cachexia.

The present disclosure provides compounds which are peptides comprising the amino acid sequence of the formula (I) disclosed herein or pharmaceutically acceptable salts thereof. The compounds act as agonists of the corticotropin-releasing factor receptor 2 (CRF2) and are useful in therapy, especially in the treatment or prevention of cardiovascular diseases, kidney disease, obesity, diabetes, sarcopenia, particularly obesity-linked sarcopenia, heart failure, cachexia, and pulmonary hypertension.

To provide safe and effective compositions and methods for enhancing the efficacy and / or reducing the side effects of cancer chemotherapy and increasing the sensitivity of chemotherapy-resistant cancer cells.SOLUTION: Nutritional supplements comprising fish oil and selenium have been found to provide various activities that are beneficial in treating cancer and related conditions. The supplement provides a synergistic effect in reducing cancer cell growth when used in combination with a chemotherapeutic agent and can reduce growth in drug resistant cancer cells when used in combination with a chemotherapeutic agent to which the cells are resistant. Effects in reducing angiogenesis, reducing metastasis, decreasing the number of circulating cancer cells, and altering AXL signaling have also been found. The use of the supplement was found to reduce the wasting associated with cachexia and decrease circulating cytokines associated with inflammation. The overall effect was found to prolong survival in a clinical study.SELECTED DRAWING: Figure 1

Nucleotide sequences including a micro-dystrophin gene are provided. The micro-dystrophin genes may be operatively linked to a regulatory cassette. Methods of treating a subject having, or at risk of developing, muscular dystrophy, sarcopenia, heart disease, or cachexia are also provided. The methods may include administering a pharmaceutical composition including the micro-dystrophin gene and a delivery vehicle to a subject. Further, the methods may include administering the pharmaceutical composition a subject having Duchenne muscular dystrophy or Becker muscular dystrophy.

The invention discloses an application of a compound or a pharmaceutical salt thereof in preparation of a medicine for preventing or treating tumor cachexia diseases. The structure of the compound is shown in the specification. The result of the embodiment of the invention shows that the compound provided by the invention can inhibit skeletal muscle atrophy so as to treat or improve tumor cachexia.

The present application relates to a composition for preventing, improving or treating cachexia or anticancer chemotherapy side effects, containing Lactobacillus reuteri ATG-F4 strain as an effective ingredient.

The invention discloses a traditional Chinese medicine composition for adjuvant therapy of tumors as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following components in parts by mass: 1-10 parts of ginseng, 1-10 parts of dendrobe, 1-15 parts of fructus amomi and 1-20 parts of coix seeds. The traditional Chinese medicine composition disclosed by the invention has an effect of relieving toxic and side effects caused by chemotherapy, such as weight loss, lifetime shortening, serum kidney injury index increase and the like. The traditional Chinese medicine composition is prepared from pure medicinal and edible traditional Chinese medicines, and is remarkable in medicine effect and few in side effect. The traditional Chinese medicine composition disclosed by the invention is rich in raw materials, simple in preparation process and low in cost, is an innovation in medicines for improving tumor malignant fluid and relieving toxic and side effects of chemotherapy medicines, and has a very good market prospect.

Use of a nucleic acid in the preparation of a drug for preventing and treating cachexia and an administration method therefor. The nucleic acid regulates in vivo cachexia-related factors by means of an oligonucleotide that the nucleic acid comprises or produces, initiates an autologous reprogramming state, regulates the activation / silencing of a key nucleic acid factor to enable a non-coding RNA regulatory signal programming network, and achieves the purpose of a single non-coding RNA regulating multiple signaling pathways, thereby enabling the establishment of new homeostasis from a dysregulated physiological state.

This invention proposes an antibody or antigen-binding fragment thereof that binds to GDF15. The antibody or antigen-binding fragment comprises: a CDR sequence selected from at least one of the following or an amino acid sequence having at least 66% identity with it: heavy chain variable region CDR sequence: SEQ ID NO: 1-34 and SEQ ID NO: 74-76; light chain variable region CDR sequence: SEQ ID NO: 36-73 and SEQ ID NO: 77-82. According to embodiments of the invention, the antibody or antigen-binding fragment thereof can specifically bind to GDF15 and effectively block the binding of GFRAL and GDF15, while also effectively inhibiting Treg differentiation, and can be used for the prevention and / or treatment of cancer and cachexia.

Disclosed are methods and compositions related to treatment, amelioration or prevention of cachexia or inflammation related to cachexia in a subject. As disclosed, cachexia or inflammation related to cachexia can be treated, ameliorated or prevented by the administration of an effective amount of a composition including immune-modulating fibroblasts to the subject.

This invention discloses GDF15 micro-binding agents and their applications. This application provides a novel class of micro-binding agents specifically targeting the GDF15-GFRAL signaling pathway. These micro-binding agents possess extremely high binding affinity, excellent structural stability, and good in vitro and in vivo functional activity. Experiments show that these micro-binding agents can significantly reverse cancer-related cachexia in various tumor models, restore body weight, and prolong survival; simultaneously, they can restore sensitivity to PD-1 immune checkpoint inhibitors and enhance CD8... + The infiltration and function of T cells in the tumor microenvironment have broad clinical application prospects.

Provided are an anti-GDF-15 antibody and the use thereof. The anti-GDF-15 antibody contains a heavy chain variable region. The heavy chain variable region contains CDR1: GFTX1X2X3X4X5; CDR2: IX6X7X8X9X10X11X12; and CDR3: X13X14X15X16X17X18X19X20X21X22X23X24X25X26X27X28X29X30X31X32X33X34. The provided antibody has a good affinity and cross-reactivity for GDF-15, effectively blocks the GDF-15 pathway, and can significantly improve cachexia in a subject. The provided bispecific antibody has a good affinity for both GDF-15 and IL-6, significantly improves cachexia in tumor-bearing mice, and alleviates an inflammatory response.

Disclosed herein is a method of treating cachexia in a subject. According to some embodiments of the present disclosure, the method includes administering to the subject an effective amount of a recombinant antibody or a fragment thereof, which exhibits a binding affinity and a neutralizing effect on parathyroid hormone-related protein. According to certain embodiments of the present disclosure, the cachexia is caused by a parathyroid hormone-related protein (PTHrP)-expressing cancer, chronic kidney disease, kidney failure, heart failure, or tuberculosis.